An observational study in Obesity (BMI > 35) and Diabetes Mellitus, Obesity (BMI > 35) and Dyslipemia and Obesity (BMI > 35) and High Blood Pressure, sponsored by Mario Musella MD. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Mario Musella MD · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 342 studies in Obesity with a site in Italy — 99 open to participants now, 118 under way, 28 of them phase 3. Obesity · Italy.
Among the 342 studies in Obesity with a site in Italy, this one is the 67th largest by planned enrollment of the 112 observational ones that give a count, is one of 2 that started in 2027, is one of 112 observational ones, reaches primary completion later than 105 of the 117 other live ones, and was the 325th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →99 of the 342 studies in Obesity with a site in Italy are open now. Recruiting first, the newest first:
Fondazione Valter Longo · Sites in Italy
Ages 14–18
Istituto Auxologico Italiano · Sites in Italy
Ages 30–70 · Healthy volunteers
Eli Lilly and Company · Sites in Italy, United States, Belgium and 7 more countries
Ages 6–11
Azienda Ospedaliero Universitaria Maggiore della Carita · Sites in Italy
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
342 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 49 · Phase 4 15
First in 1999; this study’s year is marked. 2 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 96 is below the median of 115 across 2,158 observational studies indexed under Obesity.
Median enrollment 90 across the 229 interventional studies, 120 across the 112 observational. Of the 183 that completed or were terminated, 14 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 342 have an industry lead sponsor. The 10 most frequent:
Mario Musella MD is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Mario Musella MD has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
26 of the studies in Obesity with a site in Italy that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
Add all 26 to your calendar (.ics) → With an account.
Among the 342 studies in Obesity with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study compares three preoperative strategies before one anastomosis gastric bypass(OAGB) for severe obesity. Participants will be assigned to receive either tirzepatide medication for 60 days, a ketogenic diet for 4 weeks, or standard care before surgery. The main goal is to determine which approach leads to the best weight loss one year after surgery. The study will also evaluate safety, surgical outcomes, and improvement of obesity-related health conditions such as diabetes, high blood pressure, and sleep apnea.
Obesity remains a major global health challenge. Metabolic and bariatric surgery (MBS) is the most effective treatment for severe obesity, but outcomes vary significantly among patients. This study investigates whether preoperative optimization with pharmacological treatment (tirzepatide) or dietary intervention (ketogenic diet) can improve long-term weight loss compared to proceeding directly to surgery without specific preoperative preparation.
Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown remarkable efficacy in weight reduction trials. The ketogenic diet is a very-low-calorie approach that induces rapid weight loss while preserving lean body mass. However, no randomized trial has directly compared these strategies for preoperative optimization in MBS candidates.
This multicenter randomized controlled trial will enroll 96 patients with severe obesity (BMI 45-55 kg/m²) scheduled for One Anastomosis Gastric Bypass (OAGB). Participants will be randomized 1:1:1 to three arms: (A) tirzepatide treatment for 60 days with dose escalation (2.5 mg → 5 mg → 7.5 mg weekly subcutaneous injections); (B) supervised ketogenic diet for 4 weeks (700 kcal/day with less than 50g carbohydrates); or (C) standard preoperative care without specific intervention.
All participants will undergo standardized OAGB surgery performed by experienced surgeons.
The primary endpoint is percentage of total weight loss at 12 months post-surgery. Secondary endpoints include perioperative outcomes (operative time, complications, hospital stay), resolution of obesity-related comorbidities (diabetes, hypertension, dyslipidemia, sleep apnea), nutritional status.
Randomization will be stratified by baseline BMI category, presence of type 2 diabetes, and participating center to ensure balance across important prognostic factors. Follow-up visits will occur at 30 days, 3 months, 6 months, and 12 months post-surgery with comprehensive clinical and laboratory assessments.
This study will provide crucial evidence to guide clinical decision-making regarding optimal preoperative management strategies for patients undergoing bariatric surgery, addressing the balance between potential benefits of preoperative weight loss and surgical safety.
Patients between 18 to 65 years, with Body Mass Index (BMI) between 40 and 55 kg/m² at screening visit. The patients must be eligible for bariatric surgery according to current international guidelines (IFSO 2022) with documented failure of conservative weight loss attempts. Patients enrolled need to have at least one obesity-related comorbidity and the ability to understand study procedures and provide written consent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants undergo supervised very-low-calorie ketogenic diet (VLCKD) for 4 weeks immediately before OAGB surgery.
Participants undergo standard preoperative preparation without specific medical or dietary intervention. Includes standard multidisciplinary evaluation (surgeon, dietitian, psychologist, anesthesiologist), general nutritional counseling, encouragement to maintain current weight and avoid weight gain, no structured calorie restriction or specific dietary protocol, and no GLP-1 receptor agonist or weight loss pharmacotherapy
Participants receive tirzepatide (Mounjaro®) subcutaneously once weekly for 60 days prior to OAGB surgery following dose escalation protocol: Weeks 1-4: 2.5 mg weekly; Weeks 5-8: 5 mg weekly; Week 9 (if tolerated): 7.5 mg weekly. Tirzepatide discontinued 7 days before surgery.
This study also gives Tirzepatide. No intervention listed here names it: that was found by reading the record.
Percentage of Total Weight Loss at 1 Year Post-Surgery
The primary endpoint is the percentage of total weight loss (%TWL) measured at 12 months after bariatric surgery. %TWL is calculated as: \[(Baseline Weight - Weight at 12 months) / Baseline Weight\] × 100
Time frame: 1 year
Percentage of Excess Weight Loss at 1 Year
Percentage of excess weight loss (%EWL) calculated as: \[(Baseline Weight - Weight at 12 months) / (Baseline Weight - Ideal Body Weight)\] × 100, where Ideal Body Weight is calculated using the Devine formula
Time frame: 1 year
Absolute Weight Loss at 1 Year
Absolute weight loss measured in kilograms (kg), calculated as the difference between baseline weight (at randomization) and weight at 12 months post-surgery
Time frame: 1 year
Plan to share: Yes — Study Protocol and results
Supporting information: Study protocol
Time frame: From 2029 for 1 year
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jul 2029, 30 months later.
Of 793 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 30 months is below that.
Counting every sponsor, half of 839 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mario Musella MD